Lista de obras - Mona Munteanu - Dominio Público Uruguay

A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.

artículo científico publicado en 2006

An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load

artículo científico publicado en 2008

Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age

artículo científico publicado en 2011

Applicability and variability of liver stiffness measurements according to probe position

artículo científico publicado en 2009

Assessment of liver fibrosis: noninvasive means

artículo científico publicado en 2008

Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

artículo científico publicado en 2015

Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease

artículo científico publicado en 2005

Biomarkers of liver fibrosis

artículo científico publicado en 2008

Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers

artículo científico publicado en 2008

Correction: An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load

artículo científico publicado en 2008

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference

artículo científico publicado en 2016

Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

artículo científico publicado en 2018

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

artículo científico publicado en 2006

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease

artículo científico publicado en 2006

FibroMAX: towards a new universal biomarker of liver disease?

artículo científico publicado en 2007

FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted

artículo científico publicado en 2011

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program

artículo científico publicado en 2010

Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection

artículo científico publicado en 2012

Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

artículo científico publicado en 2006

Hirsch index and truth survival in clinical research

artículo científico publicado en 2010

Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing

artículo científico publicado en 2019

Impact of steatosis and inflammation definitions on the performance of NASH tests.

artículo científico publicado en 2018

Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection

artículo científico publicado en 2010

Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest)

artículo científico publicado en 2004

Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection

artículo científico publicado en 2012

Meta-analyses of FibroTest diagnostic value in chronic liver disease

artículo científico publicado en 2007

Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

artículo científico publicado en 2011

Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.

artículo científico publicado en 2007

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C

artículo científico publicado en 2004

Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data

artículo científico publicado en 2012

Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)

artículo científico publicado en 2010

Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

artículo científico publicado en 2004

Ranking hepatologists: which Hirsch's h-index to prevent the "e-crise de foi-e"?

artículo científico publicado en 2011

Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study

artículo científico publicado en 2012

Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.

artículo científico publicado en 2016

Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up

artículo científico publicado en 2013

Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C

artículo científico publicado en 2013

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis

artículo científico publicado en 2005

The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption

artículo científico publicado en 2009

Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population

scientific article published on 18 May 2012

Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

artículo científico publicado en 2014

Lista de obras de Mona Munteanu

A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.

An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load

Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age

Applicability and variability of liver stiffness measurements according to probe position

Assessment of liver fibrosis: noninvasive means

Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease

Biomarkers of liver fibrosis

Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers

Correction: An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference

Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease

FibroMAX: towards a new universal biomarker of liver disease?

FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program

Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection

Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

Hirsch index and truth survival in clinical research

Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing

Impact of steatosis and inflammation definitions on the performance of NASH tests.

Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection

Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest)

Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection

Meta-analyses of FibroTest diagnostic value in chronic liver disease

Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C

Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data

Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)

Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

Ranking hepatologists: which Hirsch's h-index to prevent the "e-crise de foi-e"?

Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study

Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.

Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up

Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis

The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption

Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population

Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".